Abstract

REVIEW OF MOLNUPIRAVIR- AN ORAL ANTI-VIRAL DRUG FOR COVID-19

*Akanksha S. Patil, Isha K. Sankhe, Aarti R. Pawar, Krishna S. Tiwari, Priyanka Rathore and Dr. Dileep Kumar Bharati

ABSTRACT

As the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) emerged in late December 2019 in China and rapidly spread to many countries around the world. The World Health Organization (WHO) then declared this disease as a global outbreak in March 2020. As the world faces the outbreak of SARS-CoV-2, many researchers race to find the most efficacious treatment for COVID-19. Until now, the most common treatments for COVID-19 were only symptomatic such as decongestant, corticosteroid, interleukin inhibitor, and existing antiviral. Molnupiravir is an first oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main purpose of a review is to focus on the origin of the Molnupiravir drug and its activity against COVID-19 SARS-COV-2.

Keywords: Coronavirus, Molnupiravir, antiviral drug, COVID19.